1
Total investments
0
Early stage
1
Mid stage
0
Late stage
2y
Years active
Portfolio
1 investments ยท sorted by recency
All investments
Early stage
Mid stage
Late stage
Supporting Partner / Investor
Dec 2024
Calm/Storm is an exclusive founder network and boutique venture capital firm. We focus on talents, not industries.
We believe in lifelong learning & personal growth, empowering entrepreneurs with unique access to successful founders.
We are a fund built by founders for founders.
Experience ยท 4 entries
All (4)
Investments (1)
Founder (2)
2025
Scout
Sep 2025
Giant backs frontier technology founders rebuilding the foundations of civilisation. We champion entrepreneurs driven by purpose and relentless ambition to advance humanity.
There is a once-in-a-generation opportunity to redesign how the world works. Profound technological breakthroughs are accelerating amidst climate crisis, demographic upheaval and geopolitical revolution.
Giant seeks companies reimagining foundational systems: energy, materials, industry, work, finance, biology and healthcare. We invest from first cheque to growth. From AI, robotics and automation to techbio, electrification and the future of work. Giant stands for technology as a force for good, crafted by high integrity founders.
2024
Supporting Partner / Investor
Dec 2024
Calm/Storm is an exclusive founder network and boutique venture capital firm. We focus on talents, not industries.
We believe in lifelong learning & personal growth, empowering entrepreneurs with unique access to successful founders.
We are a fund built by founders for founders.
Co-Founder and CEO
Jun 2024
Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of patients are left without adequate treatment options - and AI trained with complex disease data can solve this.
2017
A
Allcyte
Chief Scientific Officer and Scientific Co-Founder
Jan 2017
